Wiki

Biothesiometry Study (Vibration Perception Threshold)

Biothesiometry Study (Vibration Perception Threshold) — 2022-11-25

Facility: Jothydev's Diabetes & Research Centre, Mudavanmugal, Thiruvananthapuram
OP No: 4096 | Ref Dr: Jothydev Kesavadev MD
Patient age at time of study: 74 years

Study Details

Biothesiometry measures vibration perception threshold (VPT) in Volts using a biothesiometer. Higher values indicate reduced vibration sensitivity, suggesting peripheral neuropathy.

Site-Specific Values (Volts)

Site RIGHT foot LEFT foot
Great toe 32 30
Ball of foot (medial) 34 27
Ball of foot (lateral) 30 26
Mid-foot (medial) 32 27
Mid-foot (center) 35 30
Heel 37 33
AVERAGE 33 V 29 V

Note: Report states "Clinically Correlated" — exact site-level anatomical assignments inferred from map layout.

Interpretation

Elevated Vibration Perception Threshold — Peripheral Neuropathy Risk

Standard interpretation thresholds (adult diabetic patients):
- <15 V: Normal
- 15–24 V: Low risk
- 25–35 V: Moderate risk (at-risk foot)
- >35 V: High risk (significant neuropathy)

Both feet fall in the moderate-risk range:
- Right foot avg 33V — upper moderate-risk range, approaching high-risk threshold
- Left foot avg 29V — mid-moderate-risk range

Individual site values: Right heel (37V) crosses into the high-risk range. Right mid-foot (35V) is at the threshold.

Conclusion: Evidence of diabetic peripheral neuropathy affecting vibration sensation as of November 2022. Right foot more affected than left.

Clinical Significance

In the context of this patient's profile:
- Biothesiometry showing 29–33V average (moderate neuropathy risk) at age 74 in 2022
- Patient was on full diabetic medication regimen at this time (Tresiba, Trajenta, Glucoformin)
- Subsequent HbA1c data (6.7% Jul 2025, 6.8% Nov 2025) suggests glucose control remained suboptimal through 2025
- Neuropathy would be expected to have progressed since this 2022 assessment — no more recent neuropathy evaluation in vault

[!note] Fall Risk Implication
Reduced vibration sensation contributes to proprioceptive deficits and fall risk — particularly significant in this 81-year-old patient currently on chemotherapy (myelosuppression, thrombocytopenia, fatigue). This baseline neuropathy assessment is relevant to the current care context.

Related Pages

Source: raw/assets/20260429_IMG_9750.jpeg